These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8965913)

  • 21. Recombinant human GM-CSF in the treatment of poorly healing wounds.
    Groves RW; Schmidt-Lucke JA
    Adv Skin Wound Care; 2000; 13(3 Pt 1):107-12. PubMed ID: 11075003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mobilization of autologous peripheral blood stem cells by chemotherapy and recombinant granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF)].
    Cui X; Shao Y; Ren B; Tong Z; Ren X; Li L; Zhang Z; Zhang N; Dai R; Hao X
    Zhonghua Xue Ye Xue Za Zhi; 2000 May; 21(5):247-9. PubMed ID: 11876989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GM-CSF autoantibodies in pulmonary alveolar proteinosis.
    Bendtzen K; Svenson M; Hansen MB
    N Engl J Med; 2007 May; 356(19):2001; author reply 2002. PubMed ID: 17494938
    [No Abstract]   [Full Text] [Related]  

  • 24. Pulmonary alveolar proteinosis.
    Trapnell BC; Whitsett JA; Nakata K
    N Engl J Med; 2003 Dec; 349(26):2527-39. PubMed ID: 14695413
    [No Abstract]   [Full Text] [Related]  

  • 25. Lack of GM-CSF as a cause of pulmonary alveolar proteinosis.
    Hallman M; Merritt TA
    J Clin Invest; 1996 Feb; 97(3):589-90. PubMed ID: 8609211
    [No Abstract]   [Full Text] [Related]  

  • 26. [alveolar proteinosis].
    Nakata K
    Nihon Naika Gakkai Zasshi; 2003 Jul; 92(7):1279-83. PubMed ID: 12924274
    [No Abstract]   [Full Text] [Related]  

  • 27. Pulmonary alveolar proteinosis in a patient with Behcet's disease.
    Uchiyama M; Nagao T; Hattori A; Fujii T; Ichiwata T; Nakata K; Tani K; Hayashi T
    Respirology; 2009 Mar; 14(2):305-8. PubMed ID: 19210651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Automated Parenchymal Pattern Analysis of Treatment Responses in Pulmonary Alveolar Proteinosis.
    McCarthy C; Bartholmai BJ; Woods JC; McCormack FX; Trapnell BC
    Am J Respir Crit Care Med; 2019 May; 199(9):1151-1152. PubMed ID: 30822107
    [No Abstract]   [Full Text] [Related]  

  • 29. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect.
    Thomassen MJ; Yi T; Raychaudhuri B; Malur A; Kavuru MS
    Clin Immunol; 2000 May; 95(2):85-92. PubMed ID: 10779401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible ocular involvement in pulmonary alveolar proteinosis.
    Perri P; Campa C; D'Angelo S; Costagliola C; Incorvaia C; Sebastiani A
    Eur Respir J; 2006 Aug; 28(2):456. PubMed ID: 16880375
    [No Abstract]   [Full Text] [Related]  

  • 31. Manmade Macrophage Offers a New Therapy for Pulmonary Alveolar Proteinosis.
    Racanelli AC; Ding BS
    Am J Respir Crit Care Med; 2018 Aug; 198(3):297-298. PubMed ID: 29669215
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effective intra-tracheal drip-infusion of acetylcystine in a case of pulmonary alveolar proteinosis].
    Nakajima T; Ito F; Tsuji S; Kobara Y
    Nihon Rinsho; 1970 Oct; 28(10):2517-22. PubMed ID: 5529048
    [No Abstract]   [Full Text] [Related]  

  • 33. Modeling pulmonary alveolar proteinosis with induced pluripotent stem cells.
    Kotton DN; Rossant J
    Am J Respir Crit Care Med; 2014 Jan; 189(2):124-6. PubMed ID: 24428646
    [No Abstract]   [Full Text] [Related]  

  • 34. Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis.
    Sewaralthahab K; Rennke H; Sewaralthahab S; Madias NE; Jaber BL
    Clin Nephrol Case Stud; 2015; 3():31-36. PubMed ID: 29043131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging Medical Therapies for Pulmonary Alveolar Proteinosis.
    Vahdatpour C; Khasawneh M; Zayed Y; Ataya A
    Am J Respir Crit Care Med; 2021 Jun; 203(12):1566-1568. PubMed ID: 33891826
    [No Abstract]   [Full Text] [Related]  

  • 36. Targeted therapy for pulmonary alveolar proteinosis: the time is now.
    Bonella F; Borie R
    Eur Respir J; 2022 Apr; 59(4):. PubMed ID: 35450922
    [No Abstract]   [Full Text] [Related]  

  • 37. Pathogenesis-driven treatment of primary pulmonary alveolar proteinosis.
    Lettieri S; Bonella F; Marando VA; Franciosi AN; Corsico AG; Campo I
    Eur Respir Rev; 2024 Jul; 33(173):. PubMed ID: 39142709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression.
    Lund-Palau H; Juarez-Molina CI; Meng C; Bhargava A; Pilou A; Aziz K; Clarke N; Atsumi N; Ashek A; Wilson MR; Takata M; Padley S; Gill DR; Hyde SC; Morgan C; Alton EWFW; Griesenbach U
    Mol Ther Methods Clin Dev; 2022 Jun; 25():382-391. PubMed ID: 35573048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Bibliometric Analysis of Pulmonary Alveolar Proteinosis From 2001 to 2021.
    Liu S; Cui X; Xia K; Wang D; Han J; Yao X; Liu X; Bian L; Zhang J; Li G
    Front Med (Lausanne); 2022; 9():846480. PubMed ID: 35391885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoimmune Pulmonary Alveolar Proteinosis.
    McCarthy C; Carey BC; Trapnell BC
    Am J Respir Crit Care Med; 2022 May; 205(9):1016-1035. PubMed ID: 35227171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.